WFA
LGND icon

Wipfli Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Wipfli Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$14K Buy
+256
New +$15K ﹤0.01% 1716

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Wipfli Financial Advisors's LGND Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2022: 256 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #1716 among its holdings.

205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

  • Wipfli Financial Advisors held 256 shares of Ligand Pharmaceuticals worth $14K as of Q3 2022.
  • Ligand Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
  • Ligand Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1716 holding.
  • 205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.